The review, led by Xu-Ran Liao and colleagues at West China Hospital of Sichuan University, synthesizes nearly a decade of single-cell and single-nucleus RNA sequencing studies of the dorsal root ganglion, or DRG, across three major causes of neuropathic pain: traumatic peripheral nerve injury, diabetic painful neuropathy, and chemotherapy-induced neuropathy. Its central message is both striking and sobering. These conditions share broad biological processes, including neuronal state remodeling, disrupted glial support, context-dependent immune responses, and extracellular matrix reorganization, but they do not converge on a single conserved molecular program. In other words, there may be no one-size-fits-all target for chronic pain, and the search for one may explain why so many promising analgesics have failed in clinical trials.

The technological shift that made this insight possible is relatively recent. Conventional bulk RNA sequencing averages gene expression across an entire tissue, blurring the signals of rare but critical cell populations such as nociceptor subtypes and infiltrating immune cells. Single-cell RNA sequencing dismantles that limitation by profiling gene expression in individual cells, revealing that the DRG contains roughly 14 to 18 conserved sensory neuron subtypes across species. These include peptidergic nociceptors marked by Calca and Tac1, non-peptidergic nociceptors defined by Mrgprd and P2rx3, and myelinated low-threshold mechanoreceptors expressing Nefh and Ntrk2/3. Single-nucleus sequencing, which profiles RNA from isolated nuclei rather than whole cells, extends this approach to frozen human tissue and better captures the large sensory neurons that are often lost during enzymatic dissociation, though it sacrifices cytoplasmic and axonally localized transcripts.

Each method carries trade-offs that shape biological interpretation. Whole-cell dissociation can preferentially exclude large or fragile myelinated neurons and artificially induces stress-response genes such as Fos and Jun, while nuclear sequencing underrepresents messages enriched in distal axons. A recent single-soma deep-sequencing strategy combining laser capture microdissection with Smart-seq2 has pushed sensitivity further, detecting on average more than 9,000 unique genes per human DRG neuron, well beyond standard nuclear approaches. Spatial transcriptomics adds another dimension, preserving the anatomical arrangement of neuronal–glial units and immune niches that dissociation destroys. The review emphasizes that batch effects from differences in sequencing depth, tissue processing, and computational pipelines remain a significant obstacle to comparing results across laboratories, models, and species.

Beyond the neurons themselves, the single-cell era has transformed understanding of the DRG’s supporting cast. Satellite glial cells, once considered a homogeneous sheath wrapping each neuronal cell body, turn out to be molecularly diverse, with distinct subtypes preferentially associating with specific neuronal classes. Some express the potassium channel Kir4.1 and preferentially ensheathe nociceptors, while others, enriched in Fabp7, cluster around large mechanoreceptors. A subpopulation expressing Ugt8 and other galactosylceramide biosynthesis enzymes contributes to the structural integrity of the neuron–glia interface through lipid metabolism. Schwann cells, meanwhile, can revert to progenitor-like repair states after injury, and one recently identified stress-response subtype, marked by high neuropeptide Y expression, appears to coordinate tissue remodeling through osteopontin signaling. Resident macrophages exist along a spectrum of activation states rather than fitting the classical M1/M2 dichotomy, and mast cells have been shown to drive neurogenic inflammation through the Mrgprb2 receptor in selected nerve-injury models.

When the review compares the three pain etiologies, the contrasts are as informative as the similarities. Peripheral nerve injury triggers a partial loss of neuronal subtype identity, robust induction of the injury marker Atf3, and activation of regeneration-associated genes including Sprr1a and Gap43. Injured neurons secrete chemokines such as Ccl2 and Csf1, recruiting Ccr2-positive monocyte-derived macrophages into the ganglion, while satellite glial cells shift toward reactive gene expression and away from cholesterol biosynthesis, potentially starving neurons of lipid support for repair. The iPain atlas has additionally identified a senescence-like nociceptor state in chronic pain models, and senolytic treatment reduced pain-related behaviors in mice, though the authors caution that behavioral improvement alone does not prove the underlying transcriptional state is reversible.

Diabetic painful neuropathy, which affects up to half of all people with diabetes, tells a different story. Here the driver is chronic metabolic stress rather than mechanical trauma, and the neuronal changes reflect altered sensory coding: clusters associated with mechanical allodynia show upregulation of Fxyd7 and Atp1b1, implicating ionic dysregulation, while aberrant Mrgprd expression in non-peptidergic neurons suggests ectopic activation of cutaneous afferents. The most distinctive feature, however, is metabolic impairment of satellite glial cells. Reduced Ugt8 expression disrupts galactosylceramide biosynthesis, weakening lipid raft integrity and the metabolic coupling between glia and neurons. In human diabetic tissue, spatial profiling of Nageotte nodules, structures long associated with advanced neuropathy, revealed that they are composed mainly of SPP1-expressing satellite glial cells and non-myelinating Schwann cells accompanying dystrophic or sprouting sensory axons, providing a human pathological correlate of multicellular degeneration. Notably, macrophages in prediabetic mice can express Trem2 and Lgals3 and may actually delay sensory axon degeneration, a protective role that contrasts sharply with the pain-promoting macrophage response seen in some nerve-injury models and argues against indiscriminate anti-inflammatory strategies.

Chemotherapy-induced neuropathy adds yet another layer of complexity, because different drugs produce different pathologies. Paclitaxel causes widespread Camk1d upregulation across sensory neuron subtypes and prominent remodeling of C-low-threshold mechanoreceptor-like neurons, with functional knockdown experiments implicating Camk1d in thermal and cold hypersensitivity. Paclitaxel also suppresses Timp3 in satellite glial cells, disinhibiting metalloproteinase signaling involving Mmp14 and Adam17 and creating a pro-inflammatory microenvironment. Bortezomib, by contrast, drives an Atf3-dependent profibrotic program in satellite glial cells of male mice, producing collagen deposition that physically constricts sensory neurons, a response linked to macrophage–glial crosstalk and far less prominent in females, which instead showed relative enrichment of lipid metabolic programs. Sex, the review stresses, is a biological variable that pain research can no longer ignore.

These findings raise an obvious question: how well do mouse data translate to humans? Human DRG atlases built from single-nucleus sequencing, spatial transcriptomics, and single-soma deep sequencing show broad conservation of major sensory neuron classes but also reveal species-specific differences that may have undermined past analgesic development. Human nociceptors display a more continuous transcriptional spectrum than the discrete peptidergic and non-peptidergic clusters seen in mice, and some human-enriched populations, including a PIEZO2-high peptidergic subtype, lack clear murine counterparts. Markers such as TRPV1 and MRGPRD show broader, less discrete expression in human tissue, meaning a target that appears restricted to one nociceptor population in mice may be more diffusely distributed in humans. The clinical example of Nav1.7 illustrates the challenge: human loss-of-function variants in SCN9A cause congenital insensitivity to pain, yet selective Nav1.7 inhibitors have shown limited efficacy in trials, possibly because the channel’s expression is concentrated in only some nociceptor populations. Meanwhile, the Nav1.8 inhibitor suzetrigine has won regulatory approval for moderate-to-severe acute pain, though its efficacy in neuropathic pain remains under investigation.

The review’s authors are candid about the limits of the field. Most single-cell studies rely on single-time-point or repeated cross-sectional sampling, which cannot establish temporal progression or causality; pseudotime analyses order cells by transcriptional state but are not equivalent to biological time, and ligand–receptor inference predicts potential communication without proving spatial proximity or receptor activation. Human DRG tissue is available mainly from organ donors with incomplete pain phenotyping, and transcript abundance does not necessarily predict protein expression, neuronal excitability, or clinical pain. The path forward, the authors argue, requires integrating longitudinal and spatial transcriptomics with human genetics, functional validation in human sensory neurons, and clinical pharmacology. The DRG cannot be routinely biopsied in living patients, so surrogate approaches such as skin-biopsy molecular profiles, circulating extracellular vesicles, and organoid models will need development, even though current organoids resemble developmental rather than adult sensory tissue. The promise is real: a new generation of mechanism-based, cell-type-informed analgesics could finally match treatments to the specific cellular programs driving each patient’s pain. But the era of single-cell pain biology is, by its own architects’ admission, still in the hypothesis-generating stage, and the hardest experiments, the ones that prove causation in human tissue, lie ahead.

Subject of Research: Single-cell and single-nucleus transcriptomic profiling of dorsal root ganglion cell-state remodeling in neuropathic pain

Article Title: Single-cell and single-nucleus transcriptomics of the dorsal root ganglion in neuropathic pain: cell-state remodeling and translational prospects

Article References: Liao, X.-R., Zheng, H., Luo, J.-Y., & Zheng, B.-X. (2026). Single-cell and single-nucleus transcriptomics of the dorsal root ganglion in neuropathic pain: cell-state remodeling and translational prospects. Journal of Translational Medicine, 24(1), Article 1126. https://doi.org/10.1186/s12967-026-08732-8

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08732-8

Keywords: neuropathic pain, dorsal root ganglion, single-cell RNA sequencing, single-nucleus RNA sequencing, satellite glial cells, nociceptors, Schwann cells, diabetic neuropathy, chemotherapy-induced neuropathy, spatial transcriptomics, neuroimmune interactions, analgesic development

The study, led by researchers at the Southern University of Science and Technology, began with a deceptively simple observation. When mice received a spinal injection of morphine, the drug rapidly increased phosphorylation, the biochemical switch that activates EphB1 receptors, in both the dorsal root ganglia, clusters of sensory neurons outside the spinal cord, and the spinal cord itself. In the dorsal root ganglia, morphine also raised levels of ephrinB2, the ligand that binds and switches on EphB1. That increase, the researchers showed, depended on the mu-opioid receptor, the very molecule through which morphine produces pain relief. In other words, morphine appears to trigger its own weakening by activating a signaling pathway that sits alongside its primary target.

To test whether EphB1 signaling actually interferes with pain relief, the team administered ephrinB2-Fc, a laboratory reagent that activates EphB1 receptors, directly into the spinal canal of mice. Even at a low dose that did not alter pain sensitivity on its own, the activator significantly blunted the analgesic effect of morphine in both the tail-flick and hot-plate tests, standard measures of pain response in rodents. Crucially, the dampening effect was selective. EphrinB2-Fc interfered with the analgesia produced by DAMGO, a drug that specifically activates mu-opioid receptors, but left untouched the effects of DPDPE and U69593, which act on the delta and kappa opioid receptor subtypes. That selectivity told the researchers that EphB1 signaling is functionally intertwined with the mu-opioid receptor in particular, not with opioid signaling in general.

The next step was to remove EphB1 and see what happened. Using genetic tools, the team created mice lacking EphB1 receptors specifically in neurons that express Vglut2, a marker of excitatory glutamatergic neurons found both in the dorsal root ganglia and in the spinal dorsal horn, the region where pain signals from the body are processed. When these mice received morphine, the analgesic effect was markedly stronger than in normal animals, while baseline pain sensitivity remained unchanged. The enhancement again applied only to DAMGO, reinforcing the link to mu-opioid receptors. The same pattern held in mouse models of disease: in animals with partial sciatic nerve ligation, a model of neuropathic pain, and in animals implanted with lung carcinoma cells in the tibia, a model of bone cancer pain, deleting EphB1 significantly strengthened morphine’s ability to reverse mechanical allodynia and thermal hyperalgesia.

To separate the peripheral and central contributions, the researchers ran parallel experiments. Crossing mice with an inducible Cre driver called Advillin allowed them to delete EphB1 exclusively in dorsal root ganglion neurons, and this too enhanced morphine analgesia. Meanwhile, injecting a Cre-expressing virus directly into the lumbar spinal cord deleted the receptor only in dorsal horn Vglut2-positive neurons, with the same result. Imaging studies supported the anatomical logic: EphB1 and the mu-opioid receptor are co-expressed in small-diameter sensory neurons, on sensory axon terminals, and in excitatory interneurons of the dorsal horn, where roughly thirty percent of Vglut2-positive neurons carried both Ephb1 and Oprm1, the gene encoding the mu-opioid receptor. Inhibitory neurons showed far less overlap.

Electrophysiology then revealed how removing EphB1 changes the behavior of individual neurons. Opioids quiet pain pathways partly by shutting down voltage-gated calcium channels in sensory neurons, which reduces the release of pain-signaling neurotransmitters. In cultured dorsal root ganglion neurons lacking EphB1, DAMGO suppressed calcium influx, measured by calcium imaging, and calcium currents, measured by patch clamp, more powerfully than in control neurons. In spinal cord slices, DAMGO’s inhibition of spontaneous excitatory synaptic currents in dorsal horn Vglut2-positive neurons was deeper without EphB1, and the drug also produced larger outward potassium currents, a hallmark of opioid receptor activation, in those neurons. Every measure pointed the same way: without EphB1, mu-opioid receptors simply work better.

The mechanism behind that improvement turned out to be receptor trafficking. When mu-opioid receptors are phosphorylated at a specific amino acid, serine 375, by enzymes called G protein-coupled receptor kinases, the adaptor protein beta-arrestin is recruited and drags the receptor off the cell surface into the interior of the cell, where it can no longer respond to morphine. The researchers found that activating EphB1 with ephrinB2-Fc pushed mu-opioid receptors out of the membrane and into the cytoplasm of cultured cells, even without any opioid drug present, and amplified the internalization triggered by DAMGO. EphB1 activation also increased phosphorylation of the receptor at serine 375, both in cell culture and in the dorsal root ganglia and spinal cords of living mice. Conversely, deleting EphB1 blunted that phosphorylation in response to DAMGO, including in the neuropathic and cancer pain models.

The missing link was GRK2, one of the G protein-coupled receptor kinases. Co-immunoprecipitation experiments showed that EphB1 receptors physically associate with GRK2 in the dorsal root ganglia and spinal cord, and that all three proteins, EphB1, GRK2, and the mu-opioid receptor, form a complex. GRK2 is heavily expressed in the same nociceptor populations that carry EphB1 and the opioid receptor. When EphB1 was activated, GRK2 became phosphorylated on tyrosine residues, a modification known to boost the enzyme’s catalytic activity, and GRK2 bound more tightly to the mu-opioid receptor. Paroxetine, an antidepressant already approved by the US Food and Drug Administration that happens to be a potent and selective GRK2 inhibitor, completely reversed the EphB1-driven phosphorylation of the opioid receptor at serine 375 and blocked the receptor internalization that followed. That result anchors the entire pathway: EphB1 activates GRK2, GRK2 phosphorylates the mu-opioid receptor, and the receptor disappears from the cell surface.

The implications reach well beyond a single experiment. Because GRK2 helps terminate signaling for hundreds of G protein-coupled receptors, the ephrin-Eph system may turn out to be a broad regulator of GPCR trafficking in many contexts, a possibility the authors flag as an exciting direction for future work. More immediately, the study offers a concrete strategy against opioid tolerance: if blocking EphB1 signaling, or inhibiting GRK2 with drugs such as paroxetine, keeps mu-opioid receptors on the neuronal surface, patients might obtain durable pain relief at lower opioid doses, reducing both escalation and overdose risk. The findings also add to a growing body of evidence that receptor tyrosine kinases, including the insulin receptor and the epidermal growth factor receptor, crosstalk with opioid receptors and shape analgesia, dependence, and reward. Translating the mouse results into the clinic will require much more work, but the identification of a druggable node in the tolerance machinery gives researchers a clear place to start.

Subject of Research: EphB1 receptor regulation of mu-opioid receptor trafficking and morphine antinociception

Article Title: EphB1 Receptor Blockade Augments Morphine Antinociception via Inhibiting GRK2‐Mediated µ‐Opioid Receptor Internalization

Article References: EphB1 Receptor Blockade Augments Morphine Antinociception via Inhibiting GRK2‐Mediated µ‐Opioid Receptor Internalization. (n.d.). https://doi.org/10.1002/advs.78099

Image Credits: AI Generated

DOI: 10.1002/advs.78099

Keywords: EphB1, morphine, opioid tolerance, mu-opioid receptor, GRK2, receptor internalization, dorsal root ganglion, spinal cord, pain, analgesia, ephrinB2, paroxetine

The study, published in BMC Neuroscience by Yujie Chen, Xinyi Gu, Sirui Tang, Huiran Zang and Guangxue Li of Peking University People’s Hospital and collaborators, set out to answer a deceptively simple question: when an RPNI is built on the end of a transected nerve, how does the rest of the nervous system respond? The technique works by wrapping the cut end of a nerve in a small, free graft of muscle. The denervated muscle fibers within the graft become reinnervated by the regenerating axons, effectively creating a living biological target that absorbs the sprouting nerves and, in principle, prevents the chaotic growth that drives neuroma pain.

What makes the new work unusual is its ambition to look beyond the surgical site. Most studies of nerve interfaces focus on the local environment of the graft, examining how well axons regenerate and how the muscle responds. The Chinese team instead performed RNA sequencing on four tissues from each animal: the reconstructed nerve itself, the dorsal root ganglion where the sensory neuron cell bodies live, the thalamus, and the hippocampus. The thalamus serves as a critical relay station for sensory signals on their way to the cortex, while the hippocampus, though best known for memory, is increasingly recognized as a site where chronic pain leaves measurable traces. By sampling all four tissues simultaneously, the researchers hoped to catch echoes of the peripheral reconstruction propagating into the central nervous system.

The experimental design was rigorous for an exploratory study of this size. Thirteen male rats were randomized into three groups. Three animals received a sham procedure, five underwent sciatic nerve transection with no reconstruction, leaving an untreated nerve stump, and five received sciatic nerve transection followed by RPNI reconstruction. Eight weeks after surgery, the team harvested the four tissues from every animal, generating fifty-two RNA sequencing libraries in total. The researchers used DESeq2, a standard statistical framework for differential expression analysis, across all fifty-two libraries, and then repeated key analyses on an overlapping thirty-six-library subset as a sensitivity check to make sure their results were not artifacts of one particular statistical choice.

The molecular results were strikingly tissue-specific. Comparing RPNI animals directly with unreconstructed stump animals, the team found 189 differentially expressed genes in the nerve itself, sixty-seven in the dorsal root ganglion, only two in the thalamus, and a mere six in the hippocampus, all using a false discovery rate threshold of five percent and a minimum absolute log2 fold change of one. In other words, the further upstream one travels from the site of reconstruction, the quieter the transcriptional signal becomes. The nerve and its associated sensory neurons show a robust molecular response to the presence of the regenerative interface, while the brain regions sampled show only faint traces of change at the gene expression level.

Yet the histology told a more nuanced story. When the researchers examined thalamic tissue under the microscope, they found that RPNI animals had significantly fewer Iba1-positive cell bodies, a marker of activated microglia, the resident immune cells of the brain that proliferate and change shape when neural injury or inflammation is present. They also counted fewer TUNEL-positive nuclei, an indicator of cell death, in the thalamus of reconstructed animals. Both differences reached statistical significance in Tukey-adjusted comparisons, with P values of 0.01602 and 0.01283 respectively. Standard hematoxylin and eosin and Nissl staining did not establish differences in overall cell counts. The microglial and cell-death findings suggest that, at the cellular level, reconstruction may be associated with a calmer central environment, even if that calm is not loudly reflected in the transcriptome of the thalamus.

Behaviorally, the picture was more ambiguous. The team scored autotomy, a behavior in which animals self-mutilate a denervated limb and a common proxy for neuropathic pain in rodent models, at four and eight weeks after surgery. Median autotomy scores were one in the RPNI group versus seven in the stump group at week four, and two versus nine at week eight. Those raw differences look dramatic, but with only five animals per group and Holm-adjusted P values of 0.1786 and 0.09524 across six comparisons, the differences did not reach conventional statistical significance. The authors are explicit that these results do not establish an analgesic effect of the procedure, even though the direction of the trend is consistent with what clinicians hope the technique can achieve.

Perhaps the most sobering findings came from the study’s cross-checks. When the researchers compared their RNA sequencing point estimates with quantitative reverse transcription PCR measurements for twenty-four candidate genes, the two methods gave estimates with opposite signs for twelve of them, half of the candidates tested. And when they searched for genes whose expression might be reversed by reconstruction across multiple tissues, they found no single gene shared across all tissues, and external comparisons against public rat nerve and mouse dorsal root ganglion datasets all yielded Benjamini-Hochberg adjusted q values of 0.30, far from significance. These results underscore how fragile exploratory signals can be when sample sizes are small and multiple tissues are interrogated at once.

The authors are admirably candid about the limits of their work. In their conclusions, they state that RPNI was associated with tissue-specific expression changes and selected thalamic histological differences, but that these exploratory findings do not establish global normalization, cross-tissue communication, or analgesic efficacy. That restraint matters in a field where enthusiasm for nerve interfaces sometimes outpaces the evidence. The study was funded by the Beijing Municipal Science and Technology Commission and the Peking University People’s Hospital Research and Development Funds, and it was approved by the institution’s animal ethics committee. The work was published open access on 28 September 2026 under a Creative Commons license.

For the growing community of surgeons and neuroscientists working on regenerative nerve interfaces, the study offers both a template and a caution. The template is the multi-tissue design itself: sampling peripheral nerve, sensory ganglia, and brain regions in the same animals provides a systems-level view that single-tissue studies cannot match. The caution is statistical: with five animals per group, only the largest effects survive correction, and the divergence between RNA sequencing and PCR measurements for half of the tested candidates shows how easily exploratory signals can mislead. Larger, adequately powered studies will be needed to determine whether the quieter thalamic microglia and the lower autotomy trends seen here mature into reliable evidence that RPNI reconstruction genuinely tames the central consequences of nerve injury. For now, the molecular echoes of reconstruction remain exactly what the authors call them: exploratory.

Subject of Research: Multi-tissue molecular and histological responses to regenerative peripheral nerve interface reconstruction after sciatic nerve transection in rats

Article Title: Exploratory multi-tissue profiling after regenerative peripheral nerve interface reconstruction in rats

Article References: Chen, Y., Gu, X., Tang, S., Zang, H., & Li, G. (2026). Exploratory multi-tissue profiling after regenerative peripheral nerve interface reconstruction in rats. BMC Neuroscience. https://doi.org/10.1186/s12868-026-01055-w

Image Credits: AI Generated

DOI: 10.1186/s12868-026-01055-w

Keywords: regenerative peripheral nerve interface, peripheral nerve injury, sciatic nerve transection, RNA sequencing, dorsal root ganglion, thalamus, microglia, neuropathic pain, autotomy, differential gene expression, neuroma prevention, rat model

The research team, led by Claudia Pérez-Calles and Jingtao Lilue, with senior authors Ashlee H. Rowe and Thomas M. Keane, built the new genomes using modern long-read sequencing and assembly approaches, producing reference-quality resources for Onychomys and its non-resistant relative. This comparative framework matters because earlier work on grasshopper mice had focused largely on a single gene family: the voltage-gated sodium channels, and in particular Nav1.8, a channel expressed in pain-sensing neurons. Previous studies had shown that structural and functional modifications of Nav1.8 in grasshopper mice block the effect of the painful toxins delivered by their scorpion prey, effectively converting a weapon of deterrence into dinner. Yet important questions remained about whether other molecular systems contribute to toxin resistance, and about how the animals respond physiologically when they are actually exposed to toxins in the wild.

By scanning the newly assembled genomes for signatures of positive selection, the researchers identified Onychomys-specific mutations in another sodium channel gene, Scn3a, which encodes the Nav1.3 channel. Unlike Nav1.8, Nav1.3 is expressed in the central nervous system and in the peripheral sensory system after nerve damage, where it is associated with heightened neuronal excitability. The discovery that grasshopper mice carry their own distinctive variants of this channel suggests that toxin resistance is not the work of a single molecular tweak but of a broader rewiring of the excitability machinery of sensory and central neurons. If Nav1.8 keeps painful toxins from firing up peripheral nociceptors, the newly identified Scn3a mutations may help ensure that any signals that do get through, or that arise from tissue damage during a scorpion battle, are blunted as well. The authors are careful to frame these as candidate adaptations whose precise functional consequences will require further experimental testing, but their recurrence in a gene so central to pain signalling makes them a compelling addition to the story.

The pangenome approach also revealed something entirely unexpected outside the nervous system: an Onychomys-specific tandem duplication of a gene called Cblif, which encodes a glycoprotein crucial for the absorption of vitamin B12 in the gut. At first glance, a vitamin transport gene seems an odd companion to toxin resistance, but the researchers connect it to the grasshopper mouse’s unusual dietary and anatomical specialisation. These rodents are carnivorous in a family dominated by seed eaters, and their stomach morphology is distinctive, characterized by an abundance of parietal cells, the acid-secreting cells of the gastric lining. The study found that Cblif is expressed in these parietal cells, and the researchers propose that the gene duplication may represent an adaptation supporting the species’ meat-rich diet and its modified stomach architecture. In an animal that consumes large quantities of arthropod prey, efficient handling of nutrients and gastric chemistry could be as important to survival as venom resistance itself, and the duplication illustrates how a pangenome can surface copy-number changes that single-reference comparisons routinely miss.

To move beyond static genome comparisons and observe the molecular response to toxin exposure as it happens, the team generated RNA sequencing data from two key sensory structures: the dorsal root ganglion, which houses the cell bodies of sensory neurons that relay pain signals from the body to the spinal cord, and the trigeminal ganglion, which performs the equivalent role for the face and head. Grasshopper mice were exposed to toxic sprays from pinacate beetles, another chemically defended prey item that these rodents subdue with gusto. The transcriptomic readout revealed that in Onychomys torridus, the southern grasshopper mouse, genes associated with transportation processes were upregulated following toxin exposure. This pattern suggests that when the animals encounter defensive chemicals, they mobilize cellular transport machinery, potentially to move toxins or their metabolites away from sensitive tissues, to shuttle protective molecules to where they are needed, or to manage the cellular stress caused by chemical assault.

Taken together, the findings sketch a multi-layered model of toxin resistance in grasshopper mice. At the first layer sit the sodium channel adaptations, with Nav1.8 modifications established by earlier work and Scn3a mutations newly identified here, that alter how pain and danger signals are generated and propagated. At the second layer sits an inducible transcriptional response, in which transport-related genes are dialled up in sensory ganglia after chemical exposure, providing a dynamic defence that complements the hard-wired channel changes. And at a third layer, the Cblif duplication hints at the digestive and metabolic specialisations that accompany a predatory lifestyle, reminding readers that adaptation to toxic prey reshapes far more than the nervous system. The authors conclude that Onychomys-specific Scn3a mutations, together with the upregulation of transport-related genes following toxin exposure, may contribute to the evolution of toxin resistance in these rodents, a formulation that is deliberately measured but nonetheless expands the known genetic substrate of the trait.

The significance of the work extends beyond one charismatic genus of desert mice. Pangenomics, the practice of building reference resources that capture the full spectrum of variation within a group of related organisms, is rapidly becoming the standard for species where a single reference genome conceals important structural differences, such as duplications, inversions and gene losses. The Onychomys study demonstrates how such resources can expose candidate adaptations that would be invisible in a conventional single-genome alignment, from tandem duplications to lineage-specific amino acid changes in physiologically critical genes. It also provides a template for studying evolutionary convergence, since toxin resistance has evolved independently in several lineages that interact with venomous prey, including other rodents, hedgehogs and opossums. Comparative work across these systems, enabled by reference-quality genomes, can help distinguish shared molecular solutions from lineage-specific innovations.

There are also potential biomedical implications. Sodium channelopathies are central to chronic pain, epilepsy and cardiac arrhythmia, and the variants that grasshopper mice have evolved under natural selection represent natural experiments in how channel function can be modified without catastrophic side effects. Understanding precisely how the Onychomys Nav1.8 and Nav1.3 variants alter channel gating, drug binding and toxin sensitivity could inform the design of new analgesics that mimic the mouse’s painlessness. Similarly, the transport genes upregulated after toxin exposure may point to endogenous detoxification and cytoprotective pathways that could be pharmacologically enhanced. The researchers caution that their results are a foundation rather than a finished edifice: functional validation, including electrophysiological characterization of the mutant channels and mechanistic dissection of the transport response, remains to be done.

For now, the grasshopper mouse has yielded another instalment of its secrets, and the picture that emerges is one of layered, genome-wide specialization. High-quality reference genomes for Onychomys species and Peromyscus eremicus now stand as public resources for the community, and the specific discoveries, from Scn3a mutations to the Cblif duplication to the toxin-induced transport response, provide a rich set of hypotheses for the next generation of experiments. What was once framed as a single-gene story about a pain-proof sodium channel has become a systems-level account of how a mammalian predator co-evolves with dangerous prey, rewiring its neurons, its digestive physiology and its stress responses in the process. As the authors and their collaborators continue to probe these adaptations, the howling little hunter of the desert may yet teach medicine a thing or two about the molecular biology of pain.

Subject of Research: Genomic adaptations underlying toxin resistance in predatory grasshopper mice (Onychomys)

Article Title: The Onychomys pangenome reveals the unique molecular adaptations that confer toxin resistance

Article References: Pérez-Calles, C., Lilue, J., Anderson, E., Haggerty, L., Martin, F. J., McCarthy, S. A., Adams, D. J., Thybert, D., Rowe, A. H., & Keane, T. M. (2026). The Onychomys pangenome reveals the unique molecular adaptations that confer toxin resistance. Genome Biology. https://doi.org/10.1186/s13059-026-04288-4

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04288-4

Keywords: grasshopper mouse, Onychomys, pangenome, toxin resistance, Nav1.8, Scn3a, sodium channels, Cblif, gene duplication, scorpion venom, dorsal root ganglion, positive selection